Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the completion of the sale, the insider now directly owns 134,021 shares of the company’s stock, valued at approximately $2,189,903.14. This represents a 6.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $14.51 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market capitalization of $1.91 billion, a PE ratio of -9.48 and a beta of 1.54. The stock has a fifty day moving average of $16.49 and a 200-day moving average of $16.41. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CNTA. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley restated an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $26.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTA. The Manufacturers Life Insurance Company lifted its position in shares of Centessa Pharmaceuticals by 88.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 264,969 shares of the company’s stock valued at $4,237,000 after acquiring an additional 124,075 shares in the last quarter. FMR LLC raised its stake in Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after purchasing an additional 129,300 shares during the period. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at $4,951,000. Suvretta Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter worth $1,119,000. Finally, Walleye Capital LLC purchased a new position in shares of Centessa Pharmaceuticals during the third quarter valued at $187,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.